

-2-

Amendments to the Claims

Please amend Claims 182, 190-192, 200 and 201. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1-145. (Canceled)

146. (Previously presented) A method of inhibiting a function of GPR-9-6 comprising contacting a cell that expresses a mammalian GPR-9-6 with an antibody or antigen-binding fragment thereof which binds said mammalian GPR-9-6 and inhibits binding of TECK to said mammalian GPR-9-6, wherein said antibody or antigen-binding fragment binds the GPR-9-6 of SEQ ID NO:2.

147. (Canceled)

148. (Previously presented) The method of Claim 146 wherein the binding of said antibody or said antigen-binding fragment to said mammalian GPR-9-6 is inhibited by a peptide that consists of the amino acid sequence of SEQ ID NO:3.

149. (Previously presented) The method of Claim 146 wherein the binding of said antibody or antigen-binding fragment to said mammalian GPR-9-6 is inhibited by mAb 3C3 (ATCC Accession No. HB-12653).

150. (Previously presented) The method of Claim 146 wherein said antibody or antigen-binding fragment has the epitopic specificity of mAb 3C3 (ATCC Accession No. HB-12653).

151. (Previously presented) The method of Claim 146 wherein the binding of said antibody or antigen-binding fragment to said mammalian GPR-9-6 is inhibited by mAb GPR96-1 (ATCC Accession No. PTA-1470).

-3-

152. (Previously presented) The method of Claim 146 wherein said antibody or antigen-binding fragment has the epitopic specificity of mAb GPR96-1 (ATCC Accession No. PTA-1470).
153. (Previously presented) The method of Claim 146 wherein said mammalian GPR-9-6 is a human GPR-9-6.
154. (Previously presented) The method of Claim 146 wherein said mammalian GPR-9-6 comprises the amino acid sequence of SEQ ID NO:2.
155. (Previously presented) The method of Claim 146 wherein said cell is a recombinant cell.
156. (Previously presented) The method of Claim 146 wherein said cell is a cell line.
157. (Previously presented) The method of Claim 156 wherein said cell line is selected from the group consisting of MOLT-4 and MOLT-13.
158. (Previously presented) The method of Claim 146 wherein said cell is a primary cell.
159. (Previously presented) The method of Claim 158 wherein said primary cell is a T cell.
160. (Previously presented) The method of Claim 146 wherein said cell that expresses a mammalian GPR-9-6 is contacted with said antibody or antigen-binding fragment thereof *in vitro*.
161. (Previously presented) The method of Claim 146 wherein said cell that expresses a mammalian GPR-9-6 is contacted with said antibody or antigen-binding fragment thereof *in vivo*.
162. (Previously presented) A method of inhibiting a function of GPR-9-6 comprising contacting a cell that expresses a mammalian GPR-9-6 with an antibody or antigen-binding fragment thereof which binds said mammalian GPR-9-6 and inhibits binding of

-4-

TECK to said mammalian GPR-9-6, wherein said mammalian GPR-9-6 is recognized by mAb 3C3 (ATCC Accession No. HB-12653) and binds TECK.

163. (Previously presented) The method of Claim 162 wherein said mammalian GPR-9-6 is a human GPR-9-6.
164. (Previously presented) The method of Claim 162 wherein said mammalian GPR-9-6 comprises the amino acid sequence of SEQ ID NO:2.
165. (Previously presented) The method of Claim 162 wherein said cell is a recombinant cell.
166. (Previously presented) The method of Claim 162 wherein said cell is a cell line.
167. (Previously presented) The method of Claim 166 wherein said cell line is selected from the group consisting of MOLT-4 and MOLT-13.
168. (Previously presented) The method of Claim 162 wherein said cell is a primary cell.
169. (Previously presented) The method of Claim 168 wherein said primary cell is a T cell.
170. (Previously presented) The method of Claim 162 wherein said cell that expresses a mammalian GPR-9-6 is contacted with said antibody or antigen-binding fragment *in vitro*.
171. (Previously presented) The method of Claim 162 wherein said cell that expresses a mammalian GPR-9-6 is contacted with said antibody or antigen-binding fragment *in vivo*.
172. (Previously presented) A method of inhibiting a function of GPR-9-6 comprising contacting a cell that expresses a mammalian GPR-9-6 with an antibody or antigen-binding fragment thereof which binds said mammalian GPR-9-6 and inhibits binding of TECK to said mammalian GPR-9-6, wherein said mammalian GPR-9-6 is recognized by mAb GPR96-1 (ATCC Accession No. PTA-1470) and binds TECK.

-5-

173. (Previously presented) The method of Claim 172 wherein said mammalian GPR-9-6 is a human GPR-9-6.
174. (Previously presented) The method of Claim 172 wherein said mammalian GPR-9-6 comprises the amino acid sequence of SEQ ID NO:2.
175. (Previously presented) The method of Claim 172 wherein said cell is a recombinant cell.
176. (Previously presented) The method of Claim 172 wherein said cell is a cell line.
177. (Previously presented) The method of Claim 176 wherein said cell line is selected from the group consisting of MOLT-4 and MOLT-13.
178. (Previously presented) The method of Claim 172 wherein said cell is a primary cell.
179. (Previously presented) The method of Claim 178 wherein said primary cell is a T cell.
180. (Previously presented) The method of Claim 172 wherein said cell that expresses a mammalian GPR-9-6 is contacted with said antibody or antigen-binding fragment *in vitro*.
181. (Previously presented) The method of Claim 172 wherein said cell that expresses a mammalian GPR-9-6 is contacted with said antibody or antigen-binding fragment *in vivo*.
182. (Currently amended) A method of inhibiting a function of GPR-9-6 comprising contacting a cell that expresses a GPR-9-6 with an antibody or antigen-binding fragment thereof that has the epitopic specificity of mAb 3C3 (ATCC Accession No. HB-12653) and inhibits binding of TECK to a GPR-9-6 encoded by SEQ ID NO:1 that binds TECK and ~~comprises an amino acid sequence that is at least about 90% similar to the amino acid sequence of SEQ ID NO:2.~~

-6-

183. (Previously presented) The method of Claim 182 wherein said GPR-9-6 is a human GPR-9-6.
184. (Previously presented) The method of Claim 182 wherein said GPR-9-6 comprises the amino acid sequence of SEQ ID NO:2.
185. (Previously presented) The method of Claim 182 wherein said cell is a recombinant cell.
186. (Previously presented) The method of Claim 182 wherein said cell is a cell line.
187. (Previously presented) The method of Claim 186 wherein said cell line is selected from the group consisting of MOLT-4 and MOLT-13.
188. (Previously presented) The method of Claim 182 wherein said cell is a primary cell.
189. (Previously presented) The method of Claim 188 wherein said primary cell is a T cell.
190. (Currently amended) The method of Claim 182 wherein said cell that expresses a mammalian GPR-9-6 is contacted with said antibody or antigen-binding fragment *in vitro*.
191. (Currently amended) The method of Claim 182 wherein said cell that expresses a mammalian GPR-9-6 is contacted with said antibody or antigen-binding fragment *in vivo*.
192. (Currently amended) A method of inhibiting a function of GPR-9-6 comprising contacting a cell that expresses a GPR-9-6 with an antibody or antigen-binding fragment thereof that has the epitopic specificity of mAb GPR96-1 (ATCC Accession No. PTA-1470) and inhibits binding of TECK to a GPR-9-6 encoded by SEQ ID NO:1 ~~that binds TECK and comprises an amino acid sequence that is at least about 90% similar to the amino acid sequence of SEQ ID NO:2.~~

-7-

193. (Previously presented) The method of Claim 192 wherein said GPR-9-6 is a human GPR-9-6.
194. (Previously presented) The method of Claim 192 wherein said GPR-9-6 comprises the amino acid sequence of SEQ ID NO:2.
195. (Previously presented) The method of Claim 192 wherein said cell is a recombinant cell.
196. (Previously presented) The method of Claim 192 wherein said cell is a cell line.
197. (Previously presented) The method of Claim 196 wherein said cell line is selected from the group consisting of MOLT-4 and MOLT-13.
198. (Previously presented) The method of Claim 192 wherein said cell is a primary cell.
199. (Previously presented) The method of Claim 198 wherein said primary cell is a T cell.
200. (Currently amended) The method of Claim 192 wherein said cell that expresses a mammalian GPR-9-6 is contacted with said antibody or antigen-binding fragment *in vitro*.
201. (Currently amended) The method of Claim 192 wherein said cell that expresses a mammalian GPR-9-6 is contacted with said antibody or antigen-binding fragment *in vivo*.
- 202-216. (Canceled)
217. (Previously presented) The method of Claim 146 wherein said antibody or antigen-binding fragment is selected from the group consisting of a human antibody, a humanized antibody, a chimeric antibody and an antigen-binding fragment of any one of the foregoing.

-8-

218. (Previously presented) The method of Claim 146 wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
219. (Previously presented) The method of Claim 162 wherein the binding of said antibody or said antigen-binding fragment to said mammalian GPR-9-6 is inhibited by a peptide that consists of the amino acid sequence of SEQ ID NO:3.
220. (Previously presented) The method of Claim 162 wherein the binding of said antibody or antigen-binding fragment to said mammalian GPR-9-6 is inhibited by mAb 3C3 (ATCC Accession No. HB-12653).
221. (Previously presented) The method of Claim 162 wherein the binding of said antibody or antigen-binding fragment to said mammalian GPR-9-6 is inhibited by mAb GPR96-1 (ATCC Accession No. PTA-1470).
222. (Previously presented) The method of Claim 162 wherein said antibody or antigen-binding fragment is selected from the group consisting of a human antibody, a humanized antibody, a chimeric antibody and an antigen-binding fragment of any one of the foregoing.
223. (Previously presented) The method of Claim 162 wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
224. (Previously presented) The method of Claim 172 wherein the binding of said antibody or said antigen-binding fragment to said mammalian GPR-9-6 is inhibited by a peptide that consists of the amino acid sequence of SEQ ID NO:3.
225. (Previously presented) The method of Claim 172 wherein the binding of said antibody or antigen-binding fragment to said mammalian GPR-9-6 is inhibited by mAb 3C3 (ATCC Accession No. HB-12653).

-9-

226. (Previously presented) The method of Claim 172 wherein the binding of said antibody or antigen-binding fragment to said mammalian GPR-9-6 is inhibited by mAb GPR96-1 (ATCC Accession No. PTA-1470).
227. (Previously presented) The method of Claim 172 wherein said antibody or antigen-binding fragment is selected from the group consisting of a human antibody, a humanized antibody, a chimeric antibody and an antigen-binding fragment of any one of the foregoing.
228. (Previously presented) The method of Claim 172 wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
229. (Previously presented) The method of Claim 182 wherein said antibody or antigen-binding fragment is selected from the group consisting of a human antibody, a humanized antibody, a chimeric antibody and an antigen-binding fragment of any one of the foregoing.
230. (Previously presented) The method of Claim 182 wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
231. (Previously presented) The method of Claim 192 wherein said antibody or antigen-binding fragment is selected from the group consisting of a human antibody, a humanized antibody, a chimeric antibody and an antigen-binding fragment of any one of the foregoing.
232. (Previously presented) The method of Claim 192 wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.